Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Department of Oncology-Pathology Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden.
Acta Oncol. 2023 Dec;62(12):1649-1652. doi: 10.1080/0284186X.2023.2264485. Epub 2023 Nov 25.
The prevalence of different HPV types, especially HPV16 and 18 in cervical cancer in patients diagnosed 2019-2023 in Stockholm was compared to corresponding data from 2003-2008 before the introduction of HPV vaccination in Sweden.
Cervical cancer samples from 125 patients diagnosed 2019-2023 in Stockholm were analysed for 27 HPV types by multiplex assay and the HPV type prevalence data was compared to data obtained in 154 cervical samples from 2003-2008.
Patient median age was higher 2019-2023 compared to 2003-2008 (55-years vs. 42-years, = 0.046). Overall HPV prevalence was 93.6%, HPV16 and 18 accounted for 62.2% of all squamous cell carcinoma cases (SCC) and 63.6% of all adenocarcinoma cases (ADC) vs. 92.9%, 69.7% and 88.6% respectively 2003-2008.
The joint prevalence of HPV16 and 18 in SCC and ADC tended to be slightly lower in 2019-2023 as compared to 2003-2008, but the difference was not statistically significant.
比较了 2019 年至 2023 年在斯德哥尔摩诊断的宫颈癌患者与 HPV 疫苗接种前的 2003 年至 2008 年相比,不同 HPV 型(尤其是 HPV16 和 18)的流行率。
通过多重分析对 2019 年至 2023 年在斯德哥尔摩诊断的 125 例宫颈癌患者的样本进行了 27 种 HPV 型分析,并将 HPV 型流行率数据与 2003 年至 2008 年的 154 例宫颈样本中获得的数据进行了比较。
2019 年至 2023 年患者的中位年龄高于 2003 年至 2008 年(55 岁对 42 岁, = 0.046)。总体 HPV 流行率为 93.6%,HPV16 和 18 占所有鳞状细胞癌(SCC)病例的 62.2%和所有腺癌(ADC)病例的 63.6%,而 2003 年至 2008 年的比例分别为 92.9%、69.7%和 88.6%。
2019 年至 2023 年 SCC 和 ADC 中 HPV16 和 18 的联合流行率略低于 2003 年至 2008 年,但差异无统计学意义。